Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCB008 in Relapsed/Refractory AML or MDS/AML (ACHIEVE2)
NCT06463327Phase 1Not yet recruiting
- Sponsor
- TC BioPharm
- Start
- Jan 2025
- Primary completion
- Jun 2026
- Modality
- Native Immune Cells
01
Overview
Phase 1, open-label trial of TCB008 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by TC BioPharm. Primary endpoints: Recommended Dose for Expansion at 29 months and Safety and Tolerability at 29 months. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
TCB008
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06463327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06463327.